Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenqi, Huang, Chen, Liu, Ruixia, Zhang, Huichao, Li, Weijing, Yin, Shaoning, Wang, Lianjing, Liu, Wei, Liu, Lihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581047/
https://www.ncbi.nlm.nih.gov/pubmed/36275715
http://dx.doi.org/10.3389/fimmu.2022.983934
_version_ 1784812530383716352
author Zhang, Wenqi
Huang, Chen
Liu, Ruixia
Zhang, Huichao
Li, Weijing
Yin, Shaoning
Wang, Lianjing
Liu, Wei
Liu, Lihong
author_facet Zhang, Wenqi
Huang, Chen
Liu, Ruixia
Zhang, Huichao
Li, Weijing
Yin, Shaoning
Wang, Lianjing
Liu, Wei
Liu, Lihong
author_sort Zhang, Wenqi
collection PubMed
description Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS relapse who received low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy followed with Bruton’s tyrosine kinase inhibitor and programmed cell death protein 1 antibody after several lines of chemotherapy. However, limited reports on CAR-T cell therapy are applied for SCNSL, particularly those in combination with targeted agents. The current treatment combination for this case provides a new regimen for CNS relapse from DLBCL. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number, NCT04666168.
format Online
Article
Text
id pubmed-9581047
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95810472022-10-20 Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma Zhang, Wenqi Huang, Chen Liu, Ruixia Zhang, Huichao Li, Weijing Yin, Shaoning Wang, Lianjing Liu, Wei Liu, Lihong Front Immunol Immunology Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS relapse who received low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy followed with Bruton’s tyrosine kinase inhibitor and programmed cell death protein 1 antibody after several lines of chemotherapy. However, limited reports on CAR-T cell therapy are applied for SCNSL, particularly those in combination with targeted agents. The current treatment combination for this case provides a new regimen for CNS relapse from DLBCL. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number, NCT04666168. Frontiers Media S.A. 2022-10-05 /pmc/articles/PMC9581047/ /pubmed/36275715 http://dx.doi.org/10.3389/fimmu.2022.983934 Text en Copyright © 2022 Zhang, Huang, Liu, Zhang, Li, Yin, Wang, Liu and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Wenqi
Huang, Chen
Liu, Ruixia
Zhang, Huichao
Li, Weijing
Yin, Shaoning
Wang, Lianjing
Liu, Wei
Liu, Lihong
Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
title Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
title_full Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
title_fullStr Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
title_full_unstemmed Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
title_short Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
title_sort case report: cd19-directed car-t cell therapy combined with btk inhibitor and pd-1 antibody against secondary central nervous system lymphoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581047/
https://www.ncbi.nlm.nih.gov/pubmed/36275715
http://dx.doi.org/10.3389/fimmu.2022.983934
work_keys_str_mv AT zhangwenqi casereportcd19directedcartcelltherapycombinedwithbtkinhibitorandpd1antibodyagainstsecondarycentralnervoussystemlymphoma
AT huangchen casereportcd19directedcartcelltherapycombinedwithbtkinhibitorandpd1antibodyagainstsecondarycentralnervoussystemlymphoma
AT liuruixia casereportcd19directedcartcelltherapycombinedwithbtkinhibitorandpd1antibodyagainstsecondarycentralnervoussystemlymphoma
AT zhanghuichao casereportcd19directedcartcelltherapycombinedwithbtkinhibitorandpd1antibodyagainstsecondarycentralnervoussystemlymphoma
AT liweijing casereportcd19directedcartcelltherapycombinedwithbtkinhibitorandpd1antibodyagainstsecondarycentralnervoussystemlymphoma
AT yinshaoning casereportcd19directedcartcelltherapycombinedwithbtkinhibitorandpd1antibodyagainstsecondarycentralnervoussystemlymphoma
AT wanglianjing casereportcd19directedcartcelltherapycombinedwithbtkinhibitorandpd1antibodyagainstsecondarycentralnervoussystemlymphoma
AT liuwei casereportcd19directedcartcelltherapycombinedwithbtkinhibitorandpd1antibodyagainstsecondarycentralnervoussystemlymphoma
AT liulihong casereportcd19directedcartcelltherapycombinedwithbtkinhibitorandpd1antibodyagainstsecondarycentralnervoussystemlymphoma

Ejemplares similares